Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Heart Lung Circ ; 23(12): 1149-52, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25086909

RESUMO

A 52 year-old male with Klinefelter syndrome presented with chest tightness and rapid atrial fibrillation with hypotension. His echocardiogram demonstrated symmetrical left ventricular hypertrophy with minimal diastolic dysfunction. Subsequent investigations confirmed the diagnosis of Fabry cardiomyopathy. This is the first reported case of Klinefelter syndrome with homozygous sex-linked recessive mutation presenting primarily with cardiac manifestation.


Assuntos
Cromossomos Humanos X/genética , Doença de Fabry/genética , Genes Recessivos , Genes Ligados ao Cromossomo X , Síndrome de Klinefelter/genética , Mutação , Doença de Fabry/patologia , Humanos , Síndrome de Klinefelter/patologia , Masculino , Pessoa de Meia-Idade
2.
Med J Aust ; 197(11): 652-4, 2012 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-23230938

RESUMO

OBJECTIVES: To evaluate the outcomes of preconception screening of Jewish Australians for Tay Sachs disease (TSD) carrier status on Jewish TSD-affected births. DESIGN, PARTICIPANTS AND SETTING: Epidemiological observational study involving a complete retrospective audit of infantile and intermediate TSD cases diagnosed in Sydney and Melbourne between 1 January 1995 and 31 December 2011 (Royal Children's Hospital Melbourne; Pacific Laboratory Medicine Services, Pathology North, NSW Health Pathology, Sydney; Victorian Clinical Genetics Services, Melbourne; and SA Pathology, Adelaide), and carrier frequency among Jewish high school students attending schools participating in TSD screening programs over the same period. MAIN OUTCOME MEASURES: Jewish TSD carrier frequency; and expected versus observed Jewish TSD-affected births. RESULTS: The 2006 Census indicated that most of the total 88,826 Jewish Australians live in Melbourne (46%) and Sydney (40%). The 7,756 Jewish high school students screened for TSD in Sydney and Melbourne during the study period had a carrier frequency of one in 31 (3.26%; 95% CI, 2.89%-3.68%).The estimated expected number of TSD-affected births in Melbourne and Sydney in 1995-2011 was 4.1 for Jewish births and 7.4 for other births (a ratio of Jewish to non-Jewish births of 1:2). The actual number was 12 (four in Sydney and eight in Melbourne), of which two were Jewish (a ratio of Jewish to non-Jewish births of 1:5). This finding of fewer than expected Jewish TSD cases coincided with a period during which screening programs were operating. There have been no Jewish TSD-affected children born to parents who were screened previously. CONCLUSION: Community education, appreciation of autosomal recessive inheritance and genetic carrier screening before pregnancy are the likely factors in our finding of fewer than expected Jewish babies with TSD. Ongoing outcome monitoring must continue.


Assuntos
Heterozigoto , Judeus/genética , Doença de Tay-Sachs/diagnóstico , Doença de Tay-Sachs/epidemiologia , Adolescente , Adulto , Austrália/epidemiologia , Feminino , Triagem de Portadores Genéticos , Testes Genéticos , Humanos , Incidência , Cuidado Pré-Concepcional , Gravidez , Diagnóstico Pré-Natal , Estudos Retrospectivos , Instituições Acadêmicas , Inquéritos e Questionários , Doença de Tay-Sachs/genética , Adulto Jovem
3.
J Med Genet ; 48(6): 422-5, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21415080

RESUMO

BACKGROUND: Lysosomal protein profiling is being developed as a high throughput method to screen populations for lysosomal storage disorders (LSD). DESIGN: 1415 blood spots from patients referred to a metabolic clinic for LSD were screened using a single multiplex assay for 14 proteins in a dried blood spot. RESULTS: All patients with Pompe disease, metachromatic leukodystrophy, and mucopolysaccharidosis (MPS) type I, IIIA, IIIB and VI were identified by reduced lysosomal protein. Five samples were identified as possible pseudo-arylsulfatase A deficiency; four were confirmed. One multiple sulfatase deficiency patient was identified with multiple reduced sulfatase proteins. There were 10 MPS II patients identified with reduced iduronate 2-sulfatase, and one MPS II patient with iduronate 2-sulfatase in the unaffected range. For Fabry disease, 10 male patients were identified with reduced α-galactosidase and 2/6 female Fabry heterozygotes returned α-galactosidase concentrations in the male Fabry range. All 10 mucolipidosis II/III patients were identified with multiple raised proteins. For 79 blood spots with chitotriosidase >3.4mg/l, a follow-up one-plex chitotriosidase assay enabled identification of all nine Gaucher patients. CONCLUSION: This study demonstrates the sensitivity and specificity of this technology to accurately identify 99% of LSD patients, with the exception of one MPS II false negative.


Assuntos
Hexosaminidases/genética , Iduronato Sulfatase/genética , Doenças por Armazenamento dos Lisossomos/diagnóstico , Doenças por Armazenamento dos Lisossomos/genética , Proteínas/genética , alfa-Galactosidase/genética , Austrália , Criança , Ensaios Enzimáticos Clínicos , Feminino , Heterogeneidade Genética , Glicosaminoglicanos/metabolismo , Hexosaminidases/sangue , Ensaios de Triagem em Larga Escala , Humanos , Iduronato Sulfatase/sangue , Imunoquímica , Recém-Nascido , Doenças por Armazenamento dos Lisossomos/sangue , Doenças por Armazenamento dos Lisossomos/epidemiologia , Masculino , Programas de Rastreamento , Mutação , Proteínas/análise , Sensibilidade e Especificidade , alfa-Galactosidase/sangue
4.
J Med Genet ; 47(9): 608-15, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20647552

RESUMO

BACKGROUND: Zellweger syndrome spectrum disorders are caused by mutations in any of at least 12 different PEX genes. This includes PEX16, which encodes an integral peroxisomal membrane protein involved in peroxisomal membrane assembly. PEX16-defective patients have been reported to have a severe clinical presentation. Fibroblasts from these patients displayed a defect in the import of peroxisomal matrix and membrane proteins, resulting in a total absence of peroxisomal remnants. OBJECTIVE: To report on six patients with an unexpected mild variant peroxisome biogenesis disorder due to mutations in the PEX16 gene. Patients presented in the preschool years with progressive spastic paraparesis and ataxia (with a characteristic pattern of progressive leucodystrophy and brain atrophy on MRI scan) and later developed cataracts and peripheral neuropathy. Surprisingly, their fibroblasts showed enlarged, import-competent peroxisomes. RESULTS: Plasma analysis revealed biochemical abnormalities suggesting a peroxisomal disorder. Biochemical variables in fibroblasts were only mildly abnormal or within the normal range. Immunofluorescence microscopy revealed the presence of import-competent peroxisomes, which were increased in size but reduced in number. Subsequent sequencing of all known PEX genes revealed five novel apparent homozygous mutations in the PEX16 gene. CONCLUSIONS: An unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene, with a relatively mild clinical phenotype and an unexpected phenotype in fibroblasts, was identified. Although PEX16 is involved in peroxisomal membrane assembly, PEX16 defects can present with enlarged import-competent peroxisomes in fibroblasts. This is important for future diagnostics of patients with a peroxisomal disorder.


Assuntos
Proteínas de Membrana/genética , Mutação/genética , Peroxissomos/genética , Peroxissomos/patologia , Adolescente , Catalase/metabolismo , Criança , Pré-Escolar , Análise Mutacional de DNA , Eritrócitos/metabolismo , Feminino , Fibroblastos/enzimologia , Fibroblastos/patologia , Imunofluorescência , Teste de Complementação Genética , Humanos , Lactente , Recém-Nascido , Imageamento por Ressonância Magnética , Masculino
6.
Mol Genet Metab ; 88(4): 307-14, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16600651

RESUMO

Lysosomal storage disorders (LSD) are chronic progressive diseases that have a devastating impact on the patient and family. Most patients are clinically normal at birth but develop symptoms early in childhood. Despite no curative treatment, a number of therapeutic options are available to improve quality of life. To achieve this, there is a pressing need for newborn screening to identify affected individuals early, before the onset of severe irreversible pathology. We have developed a multiplexed immune-quantification assay of 11 different lysosomal proteins for the identification of individuals with an LSD and evaluated this assay in a retrospective study using blood-spots from; newborns subsequently diagnosed with an LSD (n=19, six different LSD), individuals sampled after diagnosis of an LSD (n=92, 11 different LSD), newborn controls (n=433), and adult controls (n=200). All patients with mucopolysaccharidosis type I (MPS I), MPS II, MPS IIIA, MPS VI, metachromatic leukodystrophy, Niemann-Pick disease type A/B, and multiple sulfatase deficiency could be identified by reduced enzyme levels compared to controls. All mucolipidosis type II/III patients were identified by the elevation of several lysosomal enzymes, above the control range. Most Fabry, Pompe, and Gaucher disease patients were identified from either single protein differences or profiles of multiple protein markers. Newborn screening for multiple LSD is achievable using multiplexed immune-quantification of a panel of lysosomal proteins. With further validation, this method could be readily incorporated into existing screening laboratories and will have a substantial impact on patient management and counseling of families.


Assuntos
Doenças por Armazenamento dos Lisossomos/diagnóstico , Triagem Neonatal , Adulto , Estudos de Casos e Controles , Humanos , Recém-Nascido , Doenças por Armazenamento dos Lisossomos/sangue , Doenças por Armazenamento dos Lisossomos/enzimologia , Proteínas/análise , Proteínas/imunologia , Estudos Retrospectivos
7.
Expert Rev Mol Diagn ; 4(5): 677-91, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15347261

RESUMO

Lysosomal storage disorders represent a group of over 45 distinct genetic diseases. The broad spectrum of clinical presentation of this group of disorders has led to the development of diagnostic protocols to facilitate their rapid and accurate diagnosis. However, with the development of new therapies, testing for many of these disorders now extends beyond diagnosis of affected individuals. The efficacy of many current and proposed therapies will rely heavily upon early detection and treatment prior to the onset of irreversible pathology. Newborn screening holds the promise of early detection. However, presymptomatic diagnosis raises a number of issues relating to patient management and treatment. Methods for prognoses and monitoring therapy in asymptomatic individuals will be required.


Assuntos
Doenças por Armazenamento dos Lisossomos/diagnóstico , Feminino , Testes Genéticos/métodos , Humanos , Recém-Nascido , Doenças por Armazenamento dos Lisossomos/terapia , Doenças por Armazenamento dos Lisossomos/urina , Triagem Neonatal/métodos , Triagem Neonatal/tendências , Fenótipo , Gravidez , Diagnóstico Pré-Natal/métodos , Sensibilidade e Especificidade
8.
Dev Dyn ; 229(4): 780-90, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15042702

RESUMO

Mutations in the human homolog of the patched gene are associated with the developmental (and cancer predisposition) condition Nevoid Basal Cell Carcinoma Syndrome (NBCCS), as well as with sporadic basal cell carcinomas. Most mutations that have been identified in the germline of NBCCS patients are truncating or frameshift mutations, with amino acid substitutions rarely found. We show that a missense mutation in the sterol-sensing domain G509V acts as a dominant negative when assayed in vivo in Drosophila. Ectopic expression of a Drosophila patched transgene, carrying the analogous mutation to G509V, causes ectopic activation of Hedgehog target genes and ectopic membrane stabilisation of Smoothened. The G509V transgene behaves in a manner similar, except in its subcellular distribution, to a C-terminal truncation that has been characterised previously as a dominant-negative protein. G509V exhibits vesicular localisation identical to the wild-type protein, but the C-terminal truncated Patched molecule is localised predominantly to the plasma membrane. This finding suggests that dominant-negative function can be conferred by interruption of different aspects of Patched protein behaviour. Another mutation at the same residue, G509R, did not exhibit dominant-negative activity, suggesting that simple removal of the glycine at 509 is not sufficient to impart dominant-negative function.


Assuntos
Proteínas de Drosophila , Drosophila/genética , Proteínas de Membrana/genética , Mutação de Sentido Incorreto , Receptores Acoplados a Proteínas G/metabolismo , Sequência de Aminoácidos , Animais , Síndrome do Nevo Basocelular/genética , Padronização Corporal , Drosophila/crescimento & desenvolvimento , Drosophila/metabolismo , Imunofluorescência , Humanos , Proteínas de Membrana/metabolismo , Dados de Sequência Molecular , Receptores Patched , Receptor Patched-1 , Estrutura Terciária de Proteína/genética , Receptores de Superfície Celular , Receptores Acoplados a Proteínas G/genética , Glândulas Salivares/anatomia & histologia , Glândulas Salivares/citologia , Receptor Smoothened , Asas de Animais/anatomia & histologia , Asas de Animais/citologia
9.
Mol Genet Metab ; 75(1): 46-55, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11825063

RESUMO

Gaucher disease is a lysosomal storage disorder characterized by a deficiency of the enzyme acid beta-glucosidase. The clinical manifestations of Gaucher disease are highly variable, and although certain genotypes are often associated with mild or severe symptoms, a defined correlation between genotype and phenotype does not exist. Identification of biochemical markers characteristic of pathology may be of use in predicting the progression of the disease state. In this study the relationship among genotype, glycolipid substrates, lysosomal proteins, and the clinical manifestations of Gaucher disease has been evaluated. Plasma glycolipids were analyzed using electrospray ionization-tandem mass spectrometry. Lysosomal-associated membrane protein-1 (LAMP-1) and saposin C were determined by immunoquantification. Patients with Gaucher disease were shown to have an increased 16:0-glucosylceramide/16:0-lactosylceramide ratio and elevated concentrations of LAMP-1 and saposin C in plasma. A general relationship was found to exist among the 16:0-glucosylceramide/16:0-lactosylceramide ratio, LAMP-1 and saposin C levels, and patient phenotype, providing a refinement of the genotype-phenotype correlation. These findings have major implications for the diagnosis, prediction of disease severity, and monitoring of therapy in patients with Gaucher disease.


Assuntos
Doença de Gaucher/genética , Doença de Gaucher/fisiopatologia , Adolescente , Adulto , Antígenos CD/sangue , Biomarcadores , Criança , Pré-Escolar , Progressão da Doença , Feminino , Doença de Gaucher/sangue , Genótipo , Glucosilceramidas/sangue , Glicoproteínas/sangue , Humanos , Lactente , Lactosilceramidas/sangue , Proteínas de Membrana Lisossomal , Masculino , Glicoproteínas de Membrana/sangue , Pessoa de Meia-Idade , Fenótipo , Valor Preditivo dos Testes , Saposinas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...